



SPAFID
CONNECT

Informazione Regolamentata n. 0957-36-2022	Data/Ora Ricezione 06 Maggio 2022 17:26:10	Euronext Milan
--	--	----------------

Societa' : DiaSorin
Identificativo : 161788
Informazione
Regolamentata
Nome utilizzatore : DIASORINN01 - Ulisse Spada - Valerio
Vaccarone
Tipologia : REGEM
Data/Ora Ricezione : 06 Maggio 2022 17:26:10
Data/Ora Inizio : 06 Maggio 2022 17:26:11
Diffusione presunta
Oggetto : Update Annual Calendar of Corporate
Events 2022

Testo del comunicato

Please see the attachment.

DIASORIN S.P.A. – UPDATE 2022 ANNUAL CALENDAR OF CORPORATE EVENTS*

Saluggia, May 6, 2022 – Partially updating the notice submitted on April 8, 2022, please find below the annual calendar of corporate events, including the new scheduled date for approval of the Half-Yearly Financial Report and the Third Quarter 2022 results.

Board of Directors

August 3, 2022	Half-Yearly Financial Report approval
October 27, 2022	Third Quarter 2022 results approval

* Indicative dates subject to change. Any changes will be communicated without delay.

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39.0161.487567

emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. More info at www.diasoringroup.com

Fine Comunicato n.0957-36

Numero di Pagine: 3